6dw7 - Revision history

OCA at 14:37, 13 March 2024

OCA — Wed, 13 Mar 2024 14:37:21 GMT

←Older revision		Revision as of 14:37, 13 March 2024
Line 1:		Line 1:

	==SAMHD1 without Catalytic Nucleotides==		==SAMHD1 without Catalytic Nucleotides==
-	<StructureSection load='6dw7' size='340' side='right' caption='[[6dw7]], [[Resolution\|resolution]] 2.50Å' scene=''>	+	<StructureSection load='6dw7' size='340' side='right'caption='[[6dw7]], [[Resolution\|resolution]] 2.50Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6dw7]] is a 4 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DW7 OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6DW7 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6dw7]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DW7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6DW7 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=DTP:2-DEOXYADENOSINE+5-TRIPHOSPHATE'>DTP</scene>, <scene name='pdbligand=GLY:GLYCINE'>GLY</scene>, <scene name='pdbligand=GTP:GUANOSINE-5-TRIPHOSPHATE'>GTP</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene>~~</td></tr>~~	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.5Å</td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">SAMHD1, MOP5 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])~~</td></tr>	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DTP:2-DEOXYADENOSINE+5-TRIPHOSPHATE'>DTP</scene>, <scene name='pdbligand=GLY:GLYCINE'>GLY</scene>, <scene name='pdbligand=GTP:GUANOSINE-5-TRIPHOSPHATE'>GTP</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6dw7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dw7 OCA], [~~http~~://pdbe.org/6dw7 PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=6dw7 RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/6dw7 PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=6dw7 ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6dw7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dw7 OCA], [https://pdbe.org/6dw7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6dw7 RCSB], [https://www.ebi.ac.uk/pdbsum/6dw7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6dw7 ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/SAMH1_HUMAN SAMH1_HUMAN]] Defects in SAMHD1 are the cause of Aicardi-Goutieres syndrome type 5 (AGS5) [MIM:[~~http~~://omim.org/entry/612952 612952]]. A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.<ref>PMID:19525956</ref> <ref>PMID:20842748</ref> Defects in SAMHD1 are the cause of chilblain lupus type 2 (CHBL2) [MIM:[~~http~~://omim.org/entry/614415 614415]]. A rare cutaneous form of lupus erythematosus. Affected individuals present with painful bluish-red papular or nodular lesions of the skin in acral locations precipitated by cold and wet exposure at temperatures less than 10 degrees centigrade.<ref>PMID:21204240</ref>	+	[https://www.uniprot.org/uniprot/SAMH1_HUMAN SAMH1_HUMAN] Defects in SAMHD1 are the cause of Aicardi-Goutieres syndrome type 5 (AGS5) [MIM:[https://omim.org/entry/612952 612952]. A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.<ref>PMID:19525956</ref> <ref>PMID:20842748</ref> Defects in SAMHD1 are the cause of chilblain lupus type 2 (CHBL2) [MIM:[https://omim.org/entry/614415 614415]. A rare cutaneous form of lupus erythematosus. Affected individuals present with painful bluish-red papular or nodular lesions of the skin in acral locations precipitated by cold and wet exposure at temperatures less than 10 degrees centigrade.<ref>PMID:21204240</ref>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/SAMH1_HUMAN SAMH1_HUMAN]] Putative nuclease involved in innate immune response by acting as a negative regulator of the cell-intrinsic antiviral response. May play a role in mediating proinflammatory responses to TNF-alpha signaling.<ref>PMID:18546154</ref> <ref>PMID:19525956</ref>	+	[https://www.uniprot.org/uniprot/SAMH1_HUMAN SAMH1_HUMAN] Putative nuclease involved in innate immune response by acting as a negative regulator of the cell-intrinsic antiviral response. May play a role in mediating proinflammatory responses to TNF-alpha signaling.<ref>PMID:18546154</ref> <ref>PMID:19525956</ref>
-	~~<div style="background-color:#fffaf0;">~~	+
-	~~== Publication Abstract from PubMed ==~~	+
-	SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase (dNTPase) that depletes cellular dNTPs in noncycling cells to promote genome stability and to inhibit retroviral and herpes viral replication. In addition to being substrates, cellular nucleotides also allosterically regulate SAMHD1 activity. Recently, it was shown that high expression levels of SAMHD1 are also correlated with significantly worse patient responses to nucleotide analog drugs important for treating a variety of cancers, including acute myeloid leukemia (AML). In this study, we used biochemical, structural, and cellular methods to examine the interactions of various cancer drugs with SAMHD1. We found that both the catalytic and the allosteric sites of SAMHD1 are sensitive to sugar modifications of the nucleotide analogs, with the allosteric site being significantly more restrictive. We crystallized cladribine-TP, clofarabine-TP, fludarabine-TP, vidarabine-TP, cytarabine-TP, and gemcitabine-TP in the catalytic pocket of SAMHD1. We found that all of these drugs are substrates of SAMHD1 and that the efficacy of most of these drugs is affected by SAMHD1 activity. Of the nucleotide analogs tested, only cladribine-TP with a deoxyribose sugar efficiently induced the catalytically active SAMHD1 tetramer. Together, these results establish a detailed framework for understanding the substrate specificity and allosteric activation of SAMHD1 with regard to nucleotide analogs, which can be used to improve current cancer and antiviral therapies.	+
-		+
-	The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1.,Knecht KM, Buzovetsky O, Schneider C, Thomas D, Srikanth V, Kaderali L, Tofoleanu F, Reiss K, Ferreiros N, Geisslinger G, Batista VS, Ji X, Cinatl J Jr, Keppler OT, Xiong Y Proc Natl Acad Sci U S A. 2018 Oct 10. pii: 1805593115. doi:, 10.1073/pnas.1805593115. PMID:30305425<ref>PMID:30305425</ref>	+
-		+
-	~~From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>~~	+
-	~~</div>~~	+
-	~~<div class="pdbe-citations 6dw7" style="background-color:#fffaf0;"></div~~>	+
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
-	[[Category: Batista~~, V S~~]]	+	[[Category: Large Structures]]
-	[[Category: Buzovetsky, O]]	+	[[Category: Batista VS]]
-	[[Category: Cinatl, J]]	+	[[Category: Buzovetsky O]]
-	[[Category: Ferreiros, N]]	+	[[Category: Cinatl J]]
-	[[Category: Geisslinger, G]]	+	[[Category: Ferreiros N]]
-	[[Category: Ji, X]]	+	[[Category: Geisslinger G]]
-	[[Category: Kaderali, L]]	+	[[Category: Ji X]]
-	[[Category: Keppler~~, O T~~]]	+	[[Category: Kaderali L]]
-	[[Category: Knecht~~, K M~~]]	+	[[Category: Keppler OT]]
-	[[Category: Reiss, K]]	+	[[Category: Knecht KM]]
-	[[Category: Schneider, C]]	+	[[Category: Reiss K]]
-	[[Category: Srikanth, V]]	+	[[Category: Schneider C]]
-	[[Category: Thomas, D]]	+	[[Category: Srikanth V]]
-	[[Category: Tofoleanu, F]]	+	[[Category: Thomas D]]
-	[[Category: Xiong, Y]]	+	[[Category: Tofoleanu F]]
-	~~[[Category: Complex]]~~	+	[[Category: Xiong Y]]
-	~~[[Category: Deoxynucleoside triphosphate triphosphohydrolase]]~~	+
-	~~[[Category: Dntpase]]~~	+
-	~~[[Category: Hydrolase~~]]	+

OCA at 06:49, 24 October 2018

OCA — Wed, 24 Oct 2018 06:49:29 GMT

←Older revision		Revision as of 06:49, 24 October 2018
Line 3:		Line 3:
	<StructureSection load='6dw7' size='340' side='right' caption='[[6dw7]], [[Resolution\|resolution]] 2.50Å' scene=''>		<StructureSection load='6dw7' size='340' side='right' caption='[[6dw7]], [[Resolution\|resolution]] 2.50Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6dw7]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DW7 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6DW7 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6dw7]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DW7 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6DW7 FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=DTP:2-DEOXYADENOSINE+5-TRIPHOSPHATE'>DTP</scene>, <scene name='pdbligand=GLY:GLYCINE'>GLY</scene>, <scene name='pdbligand=GTP:GUANOSINE-5-TRIPHOSPHATE'>GTP</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=DTP:2-DEOXYADENOSINE+5-TRIPHOSPHATE'>DTP</scene>, <scene name='pdbligand=GLY:GLYCINE'>GLY</scene>, <scene name='pdbligand=GTP:GUANOSINE-5-TRIPHOSPHATE'>GTP</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">SAMHD1, MOP5 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6dw7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dw7 OCA], [http://pdbe.org/6dw7 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6dw7 RCSB], [http://www.ebi.ac.uk/pdbsum/6dw7 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6dw7 ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6dw7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dw7 OCA], [http://pdbe.org/6dw7 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6dw7 RCSB], [http://www.ebi.ac.uk/pdbsum/6dw7 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6dw7 ProSAT]</span></td></tr>
	</table>		</table>
Line 11:		Line 12:
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/SAMH1_HUMAN SAMH1_HUMAN]] Putative nuclease involved in innate immune response by acting as a negative regulator of the cell-intrinsic antiviral response. May play a role in mediating proinflammatory responses to TNF-alpha signaling.<ref>PMID:18546154</ref> <ref>PMID:19525956</ref>		[[http://www.uniprot.org/uniprot/SAMH1_HUMAN SAMH1_HUMAN]] Putative nuclease involved in innate immune response by acting as a negative regulator of the cell-intrinsic antiviral response. May play a role in mediating proinflammatory responses to TNF-alpha signaling.<ref>PMID:18546154</ref> <ref>PMID:19525956</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase (dNTPase) that depletes cellular dNTPs in noncycling cells to promote genome stability and to inhibit retroviral and herpes viral replication. In addition to being substrates, cellular nucleotides also allosterically regulate SAMHD1 activity. Recently, it was shown that high expression levels of SAMHD1 are also correlated with significantly worse patient responses to nucleotide analog drugs important for treating a variety of cancers, including acute myeloid leukemia (AML). In this study, we used biochemical, structural, and cellular methods to examine the interactions of various cancer drugs with SAMHD1. We found that both the catalytic and the allosteric sites of SAMHD1 are sensitive to sugar modifications of the nucleotide analogs, with the allosteric site being significantly more restrictive. We crystallized cladribine-TP, clofarabine-TP, fludarabine-TP, vidarabine-TP, cytarabine-TP, and gemcitabine-TP in the catalytic pocket of SAMHD1. We found that all of these drugs are substrates of SAMHD1 and that the efficacy of most of these drugs is affected by SAMHD1 activity. Of the nucleotide analogs tested, only cladribine-TP with a deoxyribose sugar efficiently induced the catalytically active SAMHD1 tetramer. Together, these results establish a detailed framework for understanding the substrate specificity and allosteric activation of SAMHD1 with regard to nucleotide analogs, which can be used to improve current cancer and antiviral therapies.
		+
		+	The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1.,Knecht KM, Buzovetsky O, Schneider C, Thomas D, Srikanth V, Kaderali L, Tofoleanu F, Reiss K, Ferreiros N, Geisslinger G, Batista VS, Ji X, Cinatl J Jr, Keppler OT, Xiong Y Proc Natl Acad Sci U S A. 2018 Oct 10. pii: 1805593115. doi:, 10.1073/pnas.1805593115. PMID:30305425<ref>PMID:30305425</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 6dw7" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
	[[Category: Batista, V S]]		[[Category: Batista, V S]]
	[[Category: Buzovetsky, O]]		[[Category: Buzovetsky, O]]

OCA at 08:07, 10 October 2018

OCA — Wed, 10 Oct 2018 08:07:02 GMT

←Older revision		Revision as of 08:07, 10 October 2018
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6dw7 ~~is ON HOLD until Paper Publication~~	+	==SAMHD1 without Catalytic Nucleotides==
-		+	<StructureSection load='6dw7' size='340' side='right' caption='[[6dw7]], [[Resolution\|resolution]] 2.50Å' scene=''>
-	~~Authors~~: ~~Knecht, K~~.M., ~~Buzovetsky~~, O., ~~Schneider~~, C., ~~Thomas~~, D., ~~Srikanth~~, V., ~~Kaderali, L~~., ~~Tofoleanu~~, F., ~~Reiss~~, K., ~~Ferreiros~~, N., ~~Geisslinger, G~~., ~~Batista~~, V.S.~~, Ji, X~~.~~, Cinatl, J~~.~~, Keppler, O~~.T., ~~Xiong~~, Y.	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[6dw7]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DW7 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6DW7 FirstGlance]. <br>
-	~~Description~~: ~~SAMHD1 without Catalytic Nucleotides~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=DTP:2-DEOXYADENOSINE+5-TRIPHOSPHATE'>DTP</scene>, <scene name='pdbligand=GLY:GLYCINE'>GLY</scene>, <scene name='pdbligand=GTP:GUANOSINE-5-TRIPHOSPHATE'>GTP</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
-	[[Category: ~~Unreleased Structures~~]]	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6dw7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dw7 OCA], [http://pdbe.org/6dw7 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6dw7 RCSB], [http://www.ebi.ac.uk/pdbsum/6dw7 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6dw7 ProSAT]</span></td></tr>
-	[[Category: ~~Tofoleanu~~, F]]	+	</table>
-	[[Category: ~~Xiong~~, Y]]	+	== Disease ==
-	[[Category: Keppler, O.T]]	+	[[http://www.uniprot.org/uniprot/SAMH1_HUMAN SAMH1_HUMAN]] Defects in SAMHD1 are the cause of Aicardi-Goutieres syndrome type 5 (AGS5) [MIM:[http://omim.org/entry/612952 612952]]. A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.<ref>PMID:19525956</ref> <ref>PMID:20842748</ref> Defects in SAMHD1 are the cause of chilblain lupus type 2 (CHBL2) [MIM:[http://omim.org/entry/614415 614415]]. A rare cutaneous form of lupus erythematosus. Affected individuals present with painful bluish-red papular or nodular lesions of the skin in acral locations precipitated by cold and wet exposure at temperatures less than 10 degrees centigrade.<ref>PMID:21204240</ref>
-	[[Category: ~~Batista~~, ~~V.S~~]]	+	== Function ==
		+	[[http://www.uniprot.org/uniprot/SAMH1_HUMAN SAMH1_HUMAN]] Putative nuclease involved in innate immune response by acting as a negative regulator of the cell-intrinsic antiviral response. May play a role in mediating proinflammatory responses to TNF-alpha signaling.<ref>PMID:18546154</ref> <ref>PMID:19525956</ref>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Batista, V S]]
		+	[[Category: Buzovetsky, O]]
		+	[[Category: Cinatl, J]]
		+	[[Category: Ferreiros, N]]
		+	[[Category: Geisslinger, G]]
		+	[[Category: Ji, X]]
		+	[[Category: Kaderali, L]]
		+	[[Category: Keppler, O T]]
		+	[[Category: Knecht, K M]]
	[[Category: Reiss, K]]		[[Category: Reiss, K]]
-	[[Category: Kaderali, L]]
	[[Category: Schneider, C]]		[[Category: Schneider, C]]
-	[[Category: Ji, ~~X]]~~	+	[[Category: Srikanth, V]]
-	~~[[Category: Geisslinger, G]]~~	+
-	~~[[Category: Ferreiros, N~~]]	+
	[[Category: Thomas, D]]		[[Category: Thomas, D]]
-	[[Category: ~~Cinatl~~, J]]	+	[[Category: Tofoleanu, F]]
-	[[Category: ~~Srikanth~~, V]]	+	[[Category: Xiong, Y]]
-	[[Category: ~~Buzovetsky, O~~]]	+	[[Category: Complex]]
-	[[Category: ~~Knecht, K.M~~]]	+	[[Category: Deoxynucleoside triphosphate triphosphohydrolase]]
		+	[[Category: Dntpase]]
		+	[[Category: Hydrolase]]

OCA at 05:26, 18 July 2018

OCA — Wed, 18 Jul 2018 05:26:06 GMT

←Older revision		Revision as of 05:26, 18 July 2018
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 6dw7 is ON HOLD	+	The entry 6dw7 is ON HOLD until Paper Publication

	Authors: Knecht, K.M., Buzovetsky, O., Schneider, C., Thomas, D., Srikanth, V., Kaderali, L., Tofoleanu, F., Reiss, K., Ferreiros, N., Geisslinger, G., Batista, V.S., Ji, X., Cinatl, J., Keppler, O.T., Xiong, Y.		Authors: Knecht, K.M., Buzovetsky, O., Schneider, C., Thomas, D., Srikanth, V., Kaderali, L., Tofoleanu, F., Reiss, K., Ferreiros, N., Geisslinger, G., Batista, V.S., Ji, X., Cinatl, J., Keppler, O.T., Xiong, Y.
Line 8:		Line 8:
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
	[[Category: Tofoleanu, F]]		[[Category: Tofoleanu, F]]
		+	[[Category: Xiong, Y]]
	[[Category: Keppler, O.T]]		[[Category: Keppler, O.T]]
		+	[[Category: Batista, V.S]]
	[[Category: Reiss, K]]		[[Category: Reiss, K]]
		+	[[Category: Kaderali, L]]
	[[Category: Schneider, C]]		[[Category: Schneider, C]]
		+	[[Category: Ji, X]]
	[[Category: Geisslinger, G]]		[[Category: Geisslinger, G]]
	[[Category: Ferreiros, N]]		[[Category: Ferreiros, N]]
		+	[[Category: Thomas, D]]
	[[Category: Cinatl, J]]		[[Category: Cinatl, J]]
		+	[[Category: Srikanth, V]]
	[[Category: Buzovetsky, O]]		[[Category: Buzovetsky, O]]
	[[Category: Knecht, K.M]]		[[Category: Knecht, K.M]]
-	[[Category: Xiong, Y]]
-	[[Category: Batista, V.S]]
-	[[Category: Kaderali, L]]
-	[[Category: Ji, X]]
-	[[Category: Thomas, D]]
-	[[Category: Srikanth, V]]

OCA: Protected "6dw7" [edit=sysop:move=sysop]

OCA — Wed, 04 Jul 2018 05:47:14 GMT

Protected "6dw7" [edit=sysop:move=sysop]

←Older revision

Revision as of 05:47, 4 July 2018

OCA: New page: '''Unreleased structure''' The entry 6dw7 is ON HOLD Authors: Knecht, K.M., Buzovetsky, O., Schneider, C., Thomas, D., Srikanth, V., Kaderali, L., Tofoleanu, F., Reiss, K., Ferreiros, N...

OCA — Wed, 04 Jul 2018 05:47:12 GMT

New page: '''Unreleased structure''' The entry 6dw7 is ON HOLD Authors: Knecht, K.M., Buzovetsky, O., Schneider, C., Thomas, D., Srikanth, V., Kaderali, L., Tofoleanu, F., Reiss, K., Ferreiros, N...

New page

'''Unreleased structure'''

The entry 6dw7 is ON HOLD

Authors: Knecht, K.M., Buzovetsky, O., Schneider, C., Thomas, D., Srikanth, V., Kaderali, L., Tofoleanu, F., Reiss, K., Ferreiros, N., Geisslinger, G., Batista, V.S., Ji, X., Cinatl, J., Keppler, O.T., Xiong, Y.

Description: SAMHD1 without Catalytic Nucleotides
[[Category: Unreleased Structures]]
[[Category: Tofoleanu, F]]
[[Category: Keppler, O.T]]
[[Category: Reiss, K]]
[[Category: Schneider, C]]
[[Category: Geisslinger, G]]
[[Category: Ferreiros, N]]
[[Category: Cinatl, J]]
[[Category: Buzovetsky, O]]
[[Category: Knecht, K.M]]
[[Category: Xiong, Y]]
[[Category: Batista, V.S]]
[[Category: Kaderali, L]]
[[Category: Ji, X]]
[[Category: Thomas, D]]
[[Category: Srikanth, V]]